PDS Biotechnology (PDSB) Stock: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$1.11
-0.05 (-4.31%)
âŧ
5d:
-1.77%
30d:
+38.73%
90d:
+60.24%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $1.11, which is considered fair relative to its 30-day fair value range of $0.71 to $1.26.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.90, while resistance sits at $1.79. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: PDSB scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+350.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.90, while resistance sits at $1.79. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: PDSB scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+350.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.71 -
$1.26
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 350.5% below Wall St target ($5.00)
- WARNING: Composite score 30/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.71 -
$1.26
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.79
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.22
Wall Street Target
$5.00
(+350.5%)
Share & Embed Analysis
Last updated: October 23, 2026 7:46 PM ET
Data refreshes hourly during market hours. Next update: 8:46 PM
Data refreshes hourly during market hours. Next update: 8:46 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 61 BUY |
